Achieved record annual sales exceeding $1 billion for the first time, supported by year-over-year growth across all three reporting segments.
Attributed strong Human Nutrition and Health performance to the ‘better-for-you’ consumer shift toward nutrient-dense, high-protein, and low-sugar food formulations.
Mitigated global trade and tariff volatility through a localized manufacturing model where approximately 85% of products are sold in the region of production.
Expanded international market presence significantly, with more than half of the company’s 2025 sales growth originating from markets outside the United States.
Leveraged strategic marketing partnerships with the New York Jets and Bayern Munich to reposition choline and K2 vitamins for adult cognition and women’s health.
Maintained operational consistency marking the 26th consecutive quarter of year-over-year adjusted EBITDA growth through disciplined execution.
Advanced sustainability initiatives, surpassing the 2030 greenhouse gas emission reduction goal early with a 31% reduction against the 2020 baseline.
Commenced construction of a state-of-the-art microencapsulation facility in New York to support future growth in food ingredients and nutraceuticals.
Anticipates results from over 20 active clinical studies in 2026, including high-dose choline research potentially linked to adult cognition and Alzheimer’s delay.
Plans to launch a ‘beauty-from-within’ marketing campaign for MSM, targeting the growing consumer trend in skin, hair, and nail health supplements.
Expects continued recovery in the European monogastric market following the finalization of antidumping duties on Chinese choline in late December 2025.
Maintains a capital allocation strategy prioritizing organic growth and strategic M&A, supported by a low net debt leverage ratio of 0.3.
Navigated a theoretical $20 million tariff impact, successfully reducing the actual effect to approximately $10 million through supply chain diversification.
Reported a 40 basis point decline in gross margin percentage primarily due to higher manufacturing input costs during the fourth quarter.
Increased the annual dividend by 10% to $0.96 per share, representing the 17th consecutive year of double-digit dividend growth.
Executed a share repurchase program of approximately 685,000 shares to offset equity incentive dilution and return capital to shareholders.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
